Pfizer's peak COVID sales now pegged at $50B-plus, with vaccine still hauling in $25B by 2027: analysts Oracle in talks to buy Cerner in potential $30B deal: WSJ After FDA U-turn, Amylyx eyes IPO to support ALS drug filings across the world Allergan Aesthetics completes $550M Soliton buy following FTC probe Novavax's COVID-19 vaccine scores WHO emergency listing, opening up supply to COVAX Federal appeals court revives Biden's vaccine mandate for health workers in 26 states Ipsen ends 2021 deal spree with $543M biobucks tie-up for Genfit's liver disease drug Amgen, Owkin study shows cardiac-predicting AI outperforms traditional clinical methods Biogen vows to contest EMA rejection of Aduhelm as EU regulators question weak link to Alzheimer's clinical benefit Hy-Vee latest retailer to enter telehealth and online pharmacy markets with RedBox Rx Roche's Spark unit blueprints $575M gene therapy manufacturing center in Philly V-Wave nets $98M to advance its pressure-relieving shunt implant for heart failure FDA clears Implicity’s AI heart algorithm to improve Medtronic monitors’ afib detection Featured Story | By Kevin Dunleavy What do you get when you add the omicron variant to reduced effectiveness for Regeneron and Eli Lilly antibodies and a less-than-stellar report on Merck's ballyhooed antiviral? Mammoth sales for Pfizer's COVID-19 franchise, analysts say. Think $50 billion to $60 billion at peak—and a whopping $25 billion for the vaccine alone in 2027. read more |
| |
|---|
|
|
| The PerkinElmer Biotech Bundle: advanced chemical and biologic data analytic software that represents complex data so key relationships can be better understood and decisions made with increased confidence. Learn more. |
Top Stories By Heather Landi Oracle is in talks to buy healthcare IT giant Cerner, according to people familiar with the matter, a deal that could be worth around $30 billion, the Wall Street Journal reported. read more By Kyle LaHucik Just like its approval request for a phase 2 ALS drug, Amylyx Pharmaceuticals is once again skirting convention and going forward with an initial public offering when the biotech market appears to be dipping. read more By Andrea Park The deal folds Soliton’s flagship Resonic tattoo- and cellulite-removal device into the portfolio of AbbVie's medical aesthetics subsidiary. read more By Angus Liu Novavax has taken another major step toward expanding the reach of its COVID-19 vaccine, Covovax, despite a filing delay with the U.S. FDA. read more By Heather Landi A federal appeals court has reinstated in 26 states a Biden administration vaccination mandate for health workers at hospitals that receive federal funding. A three-judge panel of the 5th U.S. Circuit Court of Appeals in New Orleans ruled that a lower court had the authority to block the mandate in only the 14 states that had sued and was wrong to impose a nationwide injunction. read more By Annalee Armstrong After a summer of deals, Ipsen is closing out the year with one last hurrah. The rare-disease-focused biopharma will partner with Genfit on a liver disease drug in a tie-up potentially worth a half-billion dollars over time. read more By Conor Hale Using information collected from more than 13,700 participants in an Amgen clinical trial, Owkin’s AI spotted which people had the highest risks of heart attacks or stroke. read more By Angus Liu Biogen knew what was coming: After a drug review committee's negative “trend vote,” a rejection of Aduhelm from EU authorities seemed inevitable. So when the rebuff did come, the biotech pounced. read more By Anastassia Gliadkovskaya The Midwestern chain of supermarkets is launching a new subsidiary to provide low-cost telehealth and online pharmacy services. read more By Annalee Armstrong Roche’s Spark Therapeutics unit is pitching $575 million into a new gene therapy manufacturing facility at Drexel University’s Philadelphia campus that will work towards the next generation of genetic medicines. read more By Conor Hale V-Wave has raised $98 million to complete the clinical testing of its implant for severe heart failure and pulmonary arterial hypertension, as well as set up the device for FDA review. read more By Andrea Park The ILR ECG Analyzer algorithm sifts through collected heart rhythm data to spot instances of atrial fibrillation and other arrhythmias with what Implicity says is greater accuracy than ICMs alone. read more | 